Mixed species biofilms of Candida albicans and Staphylococcus epidermidis

Journal of Medical Microbiology
Berit AdamL Julia Douglas

Abstract

A simple catheter disk model system was used to study the development in vitro of mixed species biofilms of Candida albicans and Staphylococcus epidermidis, two organisms commonly found in catheter-associated infections. Two strains of S. epidermidis were used: a slime-producing wild type (strain RP62A) and a slime-negative mutant (strain M7). In mixed fungal-bacterial biofilms, both staphylococcal strains showed extensive interactions with C. albicans. The susceptibility of 48-h biofilms to fluconazole, vancomycin and mixtures of the drugs was determined colorimetrically. The results indicated that the extracellular polymer produced by S. epidermidis RP62A could inhibit fluconazole penetration in mixed fungal-bacterial biofilms. Conversely, the presence of C. albicans in a biofilm appeared to protect the slime-negative staphylococcus against vancomycin. Overall, the findings suggest that fungal cells can modulate the action of antibiotics, and that bacteria can affect antifungal activity in mixed fungal-bacterial biofilms.

Citations

Feb 18, 2016·Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine·Pamela BerensAlison M Steube
Nov 26, 2010·The American Journal of the Medical Sciences·Fernanda GomesRosário Oliveira
May 27, 2014·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Hui LiShujuan Sun
Mar 7, 2012·Revista iberoamericana de micología·Consuelo Ibarra-TrujilloLuis Octavio Sánchez-Vargas
Aug 23, 2011·Trends in Microbiology·Melphine M Harriott, Mairi C Noverr
Dec 23, 2015·Journal of Medical Microbiology·Kalai MatheeGorakh Tatke
Jan 23, 2009·International Journal of Antimicrobial Agents·Xiaoqing WangSaid Jabbouri
Dec 25, 2007·Journal of Microbiological Methods·Elke PeetersTom Coenye
Aug 8, 2007·Archives of Oral Biology·Zaw M TheinLakshman P Samaranayake
Mar 13, 2014·Alimentary Pharmacology & Therapeutics·Z K WangL H Peng
Dec 29, 2013·Microbial Ecology·Lizziane Kretli WinkelströterElaine Cristina Pereira De Martinis
Jun 3, 2009·Mycoses·Z M TheinL P Samaranayake
Dec 21, 2007·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Z M TheinL P Smaranayake
Jun 15, 2013·Journal of Investigative and Clinical Dentistry·H M H N BandaraLakshman P Samaranayake
Apr 20, 2006·Archives of Oral Biology·Zaw M TheinLakshman P Samaranayake
Aug 25, 2015·FEMS Yeast Research·Lindsay E O'DonnellGordon Ramage
Jan 11, 2012·FEMS Microbiology Reviews·Sivan Elias, Ehud Banin
Jun 25, 2015·BioMed Research International·Laura Elena Carreto-BinaghiMaria Lucia Taylor
Feb 16, 2012·FEMS Immunology and Medical Microbiology·Rasmus K BojsenBirgitte Regenberg
Feb 10, 2011·Otolaryngologia polska. The Polish otolaryngology·Magdalena Nowak, Piotr Kurnatowski
Dec 29, 2004·FEMS Microbiology Letters·Hanadi LamfonJonathan Pratten
Jan 1, 2014·Pathogens and Disease·Liesbeth DemuyserPatrick Van Dijck
Jun 26, 2009·FEMS Microbiology Letters·Mark E ShirtliffMary Ann Jabra-Rizk
Jun 2, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S-H KimJ W Sohn
Apr 24, 2010·FEMS Immunology and Medical Microbiology·Iolanda Francolini, Gianfranco Donelli
Jun 5, 2016·Carbohydrate Polymers·Yulong TanBerit Schneider-Stickler
Jan 3, 2012·Fungal Biology·Fernanda Pereira Gonzales, Tim Maisch
Feb 10, 2012·International Journal of Pediatrics·Michela PaolucciVittorio Sambri
Nov 5, 2016·Colloids and Surfaces. B, Biointerfaces·Yulong TanBerit Schneider-Stickler
Aug 24, 2016·Cellular Microbiology·Toni M FörsterBernhard Hube
Oct 25, 2016·Clinical Oral Investigations·Ilona F PersoonBernd W Brandt
Nov 29, 2013·The Journal of Antimicrobial Chemotherapy·Nicolas DelattinKarin Thevissen
Apr 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rodney M Donlan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.